Officials at MilliporeSigma say the company will begin a $65 million expansion of its high potency API (HPAPI) and antibody drug conjugate (ADC) manufacturing capabilities and capacity at its facility near Madison, WI. This investment is designed to allow large-scale manufacturing of increasingly potent compounds that have the potential to treat cancer. Sourve: Genetic Engineering News 09/09/2020